
Sign up to save your podcasts
Or


He describes the benefits of prime editing, walks us through human proof-of-concept data that was announced in a patient with Chronic Granulomatous Disease, and explains the rationale to focus on Wilson's Disease, Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis, and the company's CAR-T partnership with Bristol Myers Squibb.
By BiotechTV4.3
66 ratings
He describes the benefits of prime editing, walks us through human proof-of-concept data that was announced in a patient with Chronic Granulomatous Disease, and explains the rationale to focus on Wilson's Disease, Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis, and the company's CAR-T partnership with Bristol Myers Squibb.

3,223 Listeners

1,902 Listeners

123 Listeners

324 Listeners

61 Listeners

9,960 Listeners

86 Listeners

34 Listeners

353 Listeners

19 Listeners

60 Listeners

514 Listeners

41 Listeners

0 Listeners

4 Listeners

2 Listeners

6 Listeners

46 Listeners